Name | 3-[(E)-2-(2-Thienyl)vinyl]pyrazolidine |
---|---|
Synonyms |
Pyrazolidine, 3-[(E)-2-(2-thienyl)ethenyl]-
3-[(E)-2-(2-Thienyl)vinyl]pyrazolidine |
Description | Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor[1][2]. |
---|---|
Related Catalog | |
In Vitro | Terevalefim (ANG-3777) (0-10 μM) significantly inhibited cancer cells proliferation in HUVECs[2]. Cell Viability Assay[2] Cell Line: Human Umbilical Vein Epithelial Cells (HUVECs). Concentration: 0.44, 1.78, and 7.1 μM. Incubation Time: 24 to 48 hours. Result: Dose-dependently inhibited cell proliferation. |
In Vivo | Terevalefim (ANG-3777) decreases apoptosis, increases proliferation, and promotes organ repair and function in animal models[1]. Terevalefim (ANG-3777, 40 mg/kg, IP) phosphorylates the c-Met receptor in rats[2]. Animal Model: SD rats[2]. Dosage: 40 mg/kg. Administration: IP injection, once. Result: Selectively phosphorylated the c-Met receptor and not other growth factor receptors. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 288.0±29.0 °C at 760 mmHg |
Molecular Formula | C9H8N2S |
Molecular Weight | 176.24 |
Flash Point | 128.0±24.3 °C |
Exact Mass | 180.072113 |
LogP | 1.31 |
Vapour Pressure | 0.0±0.6 mmHg at 25°C |
Index of Refraction | 1.681 |